Johnson & Johnson (JNJ) Debt to Assets Ratio: 0.24%
The debt to assets ratio for Johnson & Johnson (JNJ) is 0.24% as of Tuesday, June 9, 2026.
JNJ Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.24%
JNJ Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Johnson & Johnson (JNJ) | — | 0.24% |
| Pfizer Inc. (PFE) | $146.48B | 0.32% |
| Merck & Co., Inc. (MRK) | $295.39B | 0.37% |
| AbbVie Inc. (ABBV) | $398.27B | 0.52% |
| Eli Lilly and Company (LLY) | $1.08T | 0.38% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 0.52% |
Leverage Ratios Comparison
Debt/Assets
0.2%
Debt/Equity
0.59
Current Ratio
1.03
Interest Coverage
26.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Johnson & Johnson Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Johnson & Johnson (JNJ)?
- The debt to assets ratio for JNJ stock is 0.24%.
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato